Short Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Drops By 86.1%

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the recipient of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 228 shares, a decrease of 86.1% from the June 15th total of 1,642 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.

Basilea Pharmaceutica Price Performance

BPMUF stock remained flat at $60.27 during midday trading on Friday. The business’s fifty day moving average price is $63.66 and its two-hundred day moving average price is $67.62. The company has a current ratio of 5.11, a quick ratio of 4.68 and a debt-to-equity ratio of 0.59. Basilea Pharmaceutica has a twelve month low of $59.29 and a twelve month high of $74.00.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.

Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.